Immuneel Launches Qartemi, a CAR T-cell Therapy for Non-Hodgkin's Lymphoma in India
• Immuneel Therapeutics has launched Qartemi, India's first CAR T-cell therapy for treating adult B-cell Non-Hodgkin Lymphoma (B-NHL).
• Qartemi is a personalized therapy that modifies a patient’s T-cells to target and eliminate cancer cells, offering hope for lasting remission.
• Clinical trials in India and Spain demonstrated that Qartemi's safety and efficacy are similar to US FDA-approved CAR T-cell therapies.
• Priced at approximately ₹35 to ₹50 lakh, Qartemi is significantly more affordable than similar treatments in the US.
© Copyright 2025. All Rights Reserved by MedPath